The Green Light Committee (GLC) Initiative

What is the Green Light Committee Initiative?

One of the six components of the World Health Organization (WHO) STOP TB strategy calls for control and prevention of multidrug-resistant tuberculosis (MDR-TB) through (1) increased access to high quality 2nd-line anti-TB drugs; and (2) prevention of development of resistance to anti-TB drugs. The Green Light Committee (GLC) Initiative together with the Working Group on MDR-TB promotes implementation of this strategy as per the WHO Global Plan to Stop TB (2006-2015) and the Global MDR/XDR-TB Response plan (2007-2008).

The GLC Initiative helps countries gain access to high-quality second-line anti-TB drugs so they can provide treatment for people with multidrug-resistant tuberculosis (MDR-TB) in line with the World Health Organization (WHO) guidelines, the latest scientific evidence and country experiences. The Initiative consists of a Secretariat, the Green Light Committee (an expert review and WHO advisory body) and the Global Drug Facility (GDF) (the drug procurement arm of the Initiative).